Radius Health, Inc. (NASDAQ:RDUS) Expected to Post Quarterly Sales of $68.30 Million

Analysts predict that Radius Health, Inc. (NASDAQ:RDUSGet Rating) will announce $68.30 million in sales for the current quarter, according to Zacks. Four analysts have issued estimates for Radius Health’s earnings. The highest sales estimate is $83.46 million and the lowest is $57.39 million. Radius Health posted sales of $51.80 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 31.9%. The business is scheduled to announce its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Radius Health will report full year sales of $243.73 million for the current financial year, with estimates ranging from $233.62 million to $252.94 million. For the next fiscal year, analysts anticipate that the company will report sales of $280.13 million, with estimates ranging from $261.89 million to $318.50 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Radius Health.

Radius Health (NASDAQ:RDUSGet Rating) last announced its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.19). During the same quarter in the previous year, the business posted ($0.34) earnings per share.

RDUS has been the topic of a number of recent research reports. StockNews.com downgraded shares of Radius Health from a “buy” rating to a “hold” rating in a report on Wednesday. Zacks Investment Research downgraded shares of Radius Health from a “hold” rating to a “sell” rating and set a $6.50 target price on the stock. in a report on Wednesday. Three investment analysts have rated the stock with a sell rating and four have given a hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $11.92.

Several large investors have recently bought and sold shares of the company. Bellevue Group AG increased its holdings in shares of Radius Health by 7.1% during the 1st quarter. Bellevue Group AG now owns 8,318,714 shares of the biopharmaceutical company’s stock worth $73,454,000 after purchasing an additional 550,000 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Radius Health by 6.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 434,121 shares of the biopharmaceutical company’s stock worth $3,834,000 after purchasing an additional 26,506 shares during the period. XTX Topco Ltd bought a new position in shares of Radius Health during the 1st quarter worth about $90,000. MetLife Investment Management LLC increased its holdings in shares of Radius Health by 28.4% during the 1st quarter. MetLife Investment Management LLC now owns 23,234 shares of the biopharmaceutical company’s stock worth $205,000 after purchasing an additional 5,144 shares during the period. Finally, Acadian Asset Management LLC increased its holdings in shares of Radius Health by 341.1% during the 1st quarter. Acadian Asset Management LLC now owns 591,132 shares of the biopharmaceutical company’s stock worth $5,217,000 after purchasing an additional 457,107 shares during the period.

NASDAQ:RDUS traded up $0.03 on Monday, reaching $5.65. The stock had a trading volume of 551,912 shares, compared to its average volume of 662,707. The stock has a market cap of $268.77 million, a P/E ratio of -3.67 and a beta of 1.02. The company has a 50-day moving average of $7.86 and a 200 day moving average of $9.74. Radius Health has a 12-month low of $5.35 and a 12-month high of $23.00.

About Radius Health (Get Rating)

Radius Health, Inc, a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome.

Further Reading

Get a free copy of the Zacks research report on Radius Health (RDUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.